Filter posts

World AMR Congress Keynote Panel to Explore Making “Pull” Incentives a Reality

Here’s a statistic you might not have known: an estimated 700,000 people die each year …

Drug Importation: Dangerous for Patients, Consumers, and American Communities

Writing for The Hill, Steve Forbes, Forbes Media Chairman and Editor in Chief, delivered a …

To Ensure History Does Not Repeat Itself, Get a Flu Shot

The Centers for Disease Control and Prevention (CDC) is out with shocking new data: an …

Trump’s Drug Pricing Blueprint to be Explored at Upcoming Summit

In just a few short weeks, BIO will host its annual Patient and Health Advocacy …

Digital Health Innovation to be Spotlighted at the BIO Investor Forum

Is your company trying to expand into “digiceuticals” or digital therapeutics? Are you looking to …

UN Proposals to Weaken IP Will Not Benefit Patients

Next week the 73rd session of the United Nations General Assembly (UNGA) will convene in …

The Role – and Value – of Public-Private Partnerships in Preparedness

Nearly twelve years ago, members of the biopharmaceutical supply chain, including BIO, came together in …

Medical Research from Mars Can Fail Patients from Venus

Historically, federal dollars inadvertently flowed to medical research with a disproportionate focus on men’s health. …

Bull Market Bodes Well for #BIF18

The rapid pace of scientific discovery, FDA approvals, commercialization of medicines held long in pipelines, …

Bloomberg Exposes How Drug Cost Middlemen “Rake in Millions”

Bloomberg has authored an investigative piece exposing drug cost middlemen, better known as pharmacy benefit …